NO20005621L - Nye medikamentkombinasjoner - Google Patents

Nye medikamentkombinasjoner

Info

Publication number
NO20005621L
NO20005621L NO20005621A NO20005621A NO20005621L NO 20005621 L NO20005621 L NO 20005621L NO 20005621 A NO20005621 A NO 20005621A NO 20005621 A NO20005621 A NO 20005621A NO 20005621 L NO20005621 L NO 20005621L
Authority
NO
Norway
Prior art keywords
disorders
new drug
drug combinations
disorder
anxiety
Prior art date
Application number
NO20005621A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005621D0 (no
Inventor
Duncan Paul Taylor
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20005621L publication Critical patent/NO20005621L/no
Publication of NO20005621D0 publication Critical patent/NO20005621D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20005621A 1998-05-08 2000-11-07 Nye medikamentkombinasjoner NO20005621D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (fr) 1998-05-08 1999-04-14 Nouvelles combinaison medicamenteuses d'un inhibiteur du recaptage de la noradrenaline (nari), de preference de la reboxetine, et de pindolol

Publications (2)

Publication Number Publication Date
NO20005621L true NO20005621L (no) 2000-11-07
NO20005621D0 NO20005621D0 (no) 2000-11-07

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005621A NO20005621D0 (no) 1998-05-08 2000-11-07 Nye medikamentkombinasjoner

Country Status (22)

Country Link
EP (1) EP1075264B1 (fr)
JP (1) JP2002514601A (fr)
KR (1) KR20010052319A (fr)
CN (1) CN1300217A (fr)
AT (1) ATE283694T1 (fr)
AU (1) AU764579B2 (fr)
BR (1) BR9909559A (fr)
CA (1) CA2326105A1 (fr)
DE (1) DE69922367T2 (fr)
EA (1) EA003469B1 (fr)
ES (1) ES2232128T3 (fr)
HU (1) HUP0101341A3 (fr)
IL (1) IL139211A0 (fr)
NO (1) NO20005621D0 (fr)
NZ (1) NZ508035A (fr)
PL (1) PL345351A1 (fr)
PT (1) PT1075264E (fr)
SI (1) SI1075264T1 (fr)
SK (1) SK14502000A3 (fr)
TR (1) TR200003262T2 (fr)
WO (1) WO1999058130A1 (fr)
ZA (1) ZA200005301B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500395B1 (fr) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxétine pour traiter les fibromyalgies et d'autres troubles somatoformes
PT1632234E (pt) 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
EP1723957A3 (fr) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Dérivés de carbostyrile et inhibiteurs de réabsorption de la sérotonine pour le traitement des troubles de l'humeur
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP2429514A1 (fr) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Compositions comprenant de la transnorsertraline et des agonistes/antagonistes du récepteur 1a de la sérotonine et leurs applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.

Also Published As

Publication number Publication date
BR9909559A (pt) 2000-12-19
EA003469B1 (ru) 2003-06-26
ATE283694T1 (de) 2004-12-15
WO1999058130A1 (fr) 1999-11-18
EP1075264A1 (fr) 2001-02-14
JP2002514601A (ja) 2002-05-21
HUP0101341A2 (hu) 2001-08-28
CN1300217A (zh) 2001-06-20
PL345351A1 (en) 2001-12-17
AU764579B2 (en) 2003-08-21
SI1075264T1 (en) 2005-06-30
AU3546099A (en) 1999-11-29
KR20010052319A (ko) 2001-06-25
PT1075264E (pt) 2005-01-31
EA200001162A1 (ru) 2001-04-23
ZA200005301B (en) 2001-10-01
DE69922367D1 (de) 2005-01-05
HUP0101341A3 (en) 2006-07-28
DE69922367T2 (de) 2005-12-22
ES2232128T3 (es) 2005-05-16
IL139211A0 (en) 2001-11-25
CA2326105A1 (fr) 1999-11-18
SK14502000A3 (sk) 2001-05-10
EP1075264B1 (fr) 2004-12-01
NZ508035A (en) 2004-02-27
TR200003262T2 (tr) 2001-03-21
NO20005621D0 (no) 2000-11-07

Similar Documents

Publication Publication Date Title
Sareen et al. A review of the epidemiology and approaches to the treatment of social anxiety disorder
Shulman et al. Current place of monoamine oxidase inhibitors in the treatment of depression
Ozyalcin et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine
Brunello et al. Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment
CY1124111T1 (el) Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων
RS27704A (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
NO20100333L (no) Behandling av nevrotiske forstyrrelser
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
NO20052420L (no) Farmakologisk behandling av sovnapn±.
NO20005621L (no) Nye medikamentkombinasjoner
ATE447403T1 (de) Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
Sood et al. Diagnosis and treatment of pathologic gambling
HUP0402619A2 (hu) Norepinefrin re-uptake inhibitorok alkalmazása a megértési nehézségek kezelésére használható gyógyszer előállítására
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
WO2002040006A3 (fr) Traitement de troubles anxieux
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
HUP0101748A2 (hu) Reboxetin alkalmazása idegrendszeri zavarok kezelésére szolgáló gyógyszerkészítmények előállítására
NO20085172L (no) 3-(1h-indol-3-yl)indan-1-ylaminderivater for behandlingen av depresjon og angst
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
DE69910242D1 (de) Verwendung eines Nikotin-Rezeptor Agonisten zur Herstellung eines Medikaments zur Behandlung von Zwangsneurosen
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
NO20061427L (no) Kombinasjonen av en serotonin-reoppttaksinhibitor og amoxapin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application